Chad E. Beyer – författare
Visar alla böcker från författaren Chad E. Beyer. Handla med fri frakt och snabb leverans.
2 produkter
2 produkter
1 632 kr
Skickas inom 7-10 vardagar
Kratom: History, Science and Therapeutic Potential is the first book to address the unregulated, widespread availability of kratom, with its weak opioid and stimulant effects, coupled with limited awareness of it by healthcare professionals. Kratom has great therapeutic utility and medicinal potential, but more study, caution, and possible regulation is needed. It discusses geographical sourcing, historical uses, current worldwide uses, and potential for treatment of other medical conditions. Most exciting for healthcare professionals will be the implications of this substance's potential for treatment of diseases like depression, ADHD, PTSD, and substance-use disorder, particularly opioid use disorder (OUD).Moreover, kratom and its active alkaloid mitragynine are getting remarkable attention at federal and local governments as more than eight million Americans consume this product annually. Yet, the paucity of information for researchers and clinicians is troublesome.Provides healthcare scientists and researchers with awareness on kratom and its emerging trend as a therapy for medical use for many medical applications Presents cutting-edge science for healthcare providers of a substance that will soon be as topical as medical marijuanaOffers scientists and others information to help those involved in emerging decisions regarding legal status and regulations
Next Generation Antidepressants
Moving Beyond Monoamines to Discover Novel Treatment Strategies for Mood Disorders
Inbunden, Engelska, 2010
1 773 kr
Skickas inom 7-10 vardagar
The World Health Organization defines depression as a primary contributor to the global burden of disease and predicts it will become the second leading cause of death by 2020. The need to develop effective therapies has never been so pressing. Current antidepressant drugs have several limitations. This 2010 book looks at the future of mood-disorder research, covering the identification of new therapeutic targets, establishing new preclinical models, new medicinal chemistry opportunities, and fostering greater understanding of genetic influences. These strategies are likely to help build a better picture of the disease process, and lead to new opportunities for patient stratification and treatment. The ultimate goal for this strand of research is to develop more personalized and effective treatments for this chronic and debilitating condition. This is essential reading for all those involved in psychopharmacologic drug development, and mental health clinicians seeking a preview of discoveries soon to influence their practice.